Last reviewed: May 12, 2026 Last updated: May 12, 2026 Written by: Jay Hastings , CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations....

Hers accepts HSA/FSA via reimbursement (pay with regular card, submit receipt). PlexusDx accepts HSA/FSA card payment at checkout where your plan permits, with no membership fee — protocols from $129/mo, all 50 states.

The seven non-negotiable questions to ask before any GLP-1 telehealth consult, with green/yellow/red answer guides — pharmacy identity (503A vs 503B), compounded vs FDA-approved, total cost across month one through highest maintenance dose, escalation path, and the genetic-baseline question most cash-pay platforms skip.

MEDVi vs Hers vs PlexusDx in 2026: real annual cost math, compounded vs FDA-approved branded medication source, tirzepatide availability across all three, cancellation and refund policy differences, and where the Precision Peptide Genetic Test fits when GLP-1 response varies by GIPR, FTO, MC4R, and TCF7L2 variants.

MEDVi’s ongoing compounded semaglutide rate is $299/month, with multi-month prepaid plans also offered. We reconcile MEDVi’s pricing against PlexusDx Semaglutide Injection ($189/mo) and Semaglutide Oral ($289/mo) on a 12-month total-cost basis — with the genetic baseline MEDVi doesn’t offer.

Pennsylvania Medicaid cut GLP-1 coverage for adult weight loss on January 1, 2026. This guide walks the legal cash-pay telehealth options that ship to PA, the compounded vs FDA-approved branded distinction, real annualized costs, and where PlexusDx Microdose GLP-1 ($129/mo), Semaglutide Injection ($189/mo), and Tirzepatide Injection ($289/mo) sit relative to Eden, Ro, TrimRx, Willow, and MEDVi — with the optional Precision Peptide Genetic Test adding pathway-level genetic context before week one.